The 2026 meningococcal serogroup B cluster in the United Kingdom: a case for strategic reform

Invasive meningococcal disease (IMD) is re-emerging in the United Kingdom following suppression during the COVID-19 pandemic. In early 2026, an atypical outbreak of meningococcal serogroup B (MenB) disease occurred among adolescents and young adults in Kent, representing the most significant meningococcal incident in England in recent years. The outbreak was linked to intense social mixing in nightlife and university settings, resulting in multiple confirmed cases and fatalities, cross-border exposure, and extensive public health intervention including mass chemoprophylaxis and targeted vaccination. Despite the UK’s comparatively strong meningococcal immunisation programme, the outbreak highlighted persistent vulnerabilities: waning infant MenB protection by adolescence, suboptimal MenACWY uptake in school-aged cohorts, delays in notification, and outbreak response systems poorly adapted to highly mobile student populations. Surveillance data indicate IMD has returned to near pre-pandemic levels, driven predominantly by MenB, while serogroups covered by adolescent MenACWY vaccination remain suppressed. This outbreak underscores the need to re-evaluate adolescent MenB vaccination policy, strengthen catch-up vaccination delivery, modernise outbreak communication and surveillance systems, and anticipate equitable access to vaccines during periods of heightened demand. Without strategic reform, similar outbreaks are likely to recur as IMD incidence rises.